|
Video: What is a Stock Split?
|
|
ABVC BioPharma is a clinical stage biopharmaceutical company. Co.'s wholly owned subsidiaries, American BriVision Corporation, focuses on the development of ABV-1701 Vitreous Substitute for Vitrectomy. Through its another wholly owned subsidiary, BioLite Holding Inc., Co. conducts clinical research and trials of various drug candidates, including: ABV-1504 for the treatment of Major Depressive Disorder, ABV-1505 to treat Attention-Deficit Hyperactivity Disease, ABV-1501 for the treatment of Triple Negative Breast Cancer, ABV-1703 for the treatment of Pancreatic Cancer, ABV-1702 to treat Myelodysplastic syndromes and ABV-1601 Depression in Cancer Patients. According to our ABVC split history records, ABVC BioPharma has had 1 split. | |
|
ABVC BioPharma (ABVC) has 1 split in our ABVC split history database. The split for ABVC took place on July 25, 2023. This was a 1 for 10 reverse split, meaning for each 10 shares of ABVC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as ABVC BioPharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ABVC split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ABVC BioPharma shares, starting with a $10,000 purchase of ABVC, presented on a split-history-adjusted basis factoring in the complete ABVC split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/06/2021 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$50.50 |
|
End price/share: |
$1.42 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.19% |
|
Average Annual Total Return: |
-66.10% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$281.20 |
|
Years: |
3.30 |
|
|
|
Date |
Ratio |
07/25/2023 | 1 for 10 |
|
|